Pathophysiology and management of risperidone-induced sialorrhea: case report.
| Autor: | Torrico T; Kern Medical, Department of Psychiatry, Bakersfield, CA, United States.; American Psychiatric Association Substance Abuse and Mental Health Services Administration (SAMHSA) Minority Fellowship, Washington, DC, United States., Kahlon A; Kern Medical, Department of Psychiatry, Bakersfield, CA, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in psychiatry [Front Psychiatry] 2023 Jul 13; Vol. 14, pp. 1185750. Date of Electronic Publication: 2023 Jul 13 (Print Publication: 2023). |
| DOI: | 10.3389/fpsyt.2023.1185750 |
| Abstrakt: | Background: Among antipsychotics, sialorrhea is most associated with clozapine, and when it occurs, it is uncomfortable, socially stigmatizing, and can contribute to medication non-adherence. Risperidone has a generally negligible muscarinic activity compared to clozapine, and yet, multiple reports of severe sialorrhea associated with risperidone have been reported. Case Presentation: This case report describes risperidone-induced sialorrhea that was unintentionally masked by simultaneous clonidine administration that was intended to treat hypertension. Interestingly, sialorrhea was present but mild when clonidine was present; however, when risperidone was further titrated and clonidine removed, a significant worsening of sialorrhea developed. Sialorrhea did not respond to treatment with anticholinergic medication. Conclusion: The pathophysiology of antipsychotic-induced sialorrhea is complex and varies between antipsychotics. Risperidone-induced sialorrhea is suspected of having prominent adrenergic pathophysiology that is likely composed of highly viscoelastic saliva (high protein content), differing from the more commonly encountered clozapine-induced sialorrhea. Risperidone-induced sialorrhea is reported as more likely to respond to dose reduction and treatment with α2-adrenergic receptor agonists or β-adrenergic receptor antagonists and less likely to respond to anticholinergic (antimuscarinic) medications. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Torrico and Kahlon.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|